MITOMYCIN FOR INJECTION

There is only one Canadian supplier of mitomycin for injection\(^1\) (see below). Although listed in the Drug Product Database, Hospira is not currently marketing its brand of mitomycin in Canada.\(^2\)

<table>
<thead>
<tr>
<th>DIN</th>
<th>Company</th>
<th>Product</th>
<th>Active Ingredient</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>02230450</td>
<td>TEVA CANADA LIMITED</td>
<td>MITOMYCIN FOR INJECTION</td>
<td>MITOMYCIN</td>
<td>5 MG / VIAL</td>
</tr>
<tr>
<td>02230451</td>
<td>TEVA CANADA LIMITED</td>
<td>MITOMYCIN FOR INJECTION</td>
<td>MITOMYCIN</td>
<td>20 MG / VIAL</td>
</tr>
</tbody>
</table>

**Labelled Indications**\(^3,4\):
- Adjunct palliative treatment for adenocarcinoma of stomach and colon
- Topical therapy for superficial carcinoma of the urinary bladder

**Off-label Indications**\(^3,5\):
- Treatment of various cancers
- Prevention of scarring in glaucoma surgery; prevention of corneal haze after refractive surgery
- Topical treatment of tracheal stenosis

**Shortage management:**

**Extemporaneous preparation:** High risk product due to cytotoxicity.\(^3\)

- 0.5 mg/ml solutions prepared with Sterile Water for Injection are stable for 1 week at room temperature and 2 weeks refrigerated. Protect from light.\(^3\)
- When diluted to 20 to 40 mcg/ml, stable for 3 hours in D5W and 12 hours in Normal Saline at room temperature.\(^3\)
- As long as bulk chemical remains available, compounding pharmacies can prepare the injectable formulation.\(^6\)

**Therapeutic Alternatives:**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Alternative</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer treatment</td>
<td>No single agent can be substituted for mitomycin(^5)</td>
<td>Choice of alternative must be patient-specific and based on renal function, liver function, and the neoplasm type and location.(^5)</td>
</tr>
<tr>
<td></td>
<td>If considering use of mitomycin in combination, ensure adequate supply of mitomycin on hand to complete treatment before starting; if not, select alternative protocol.(^5)</td>
<td></td>
</tr>
<tr>
<td>Glaucoma surgery (trabeculectomy)</td>
<td>5-fluorouracil(^7)</td>
<td>Evaluate need for antifibrotic agent; reserve use for high risk patients(^9)</td>
</tr>
<tr>
<td></td>
<td>Bevacizumab(^8)</td>
<td></td>
</tr>
</tbody>
</table>

---
Refractive surgery

- Ophthalmic corticosteroids e.g. fluorometholone
- Reserve mitomycin for high risk patients – severe myopia, deeper ablation

Tracheal stenosis

- Benefit of mitomycin for this indication is questionable

References: